Delving into the Latest Updates on House dust mites allergenics extract(ALK-Abello A/S) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

ACARIZAX, ALK HDM, ALK Mite Tablet

+ [14]

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [3]

Active Indication

AsthmaConjunctivitisEpilepsy, Idiopathic Generalized+ [3]

Inactive Indication

Allergic asthmaAllergic rhinoconjunctivitisAnaphylaxis+ [2]

Originator Organization

ALK-Abello A/S

Active Organization

Abbott Laboratories

ALK-Abello A/SSeqirus GmbH

+ [1]

Inactive Organization

Merck Sharp & Dohme Corp.Danish Alkai--Abeyo Company Beijing Representative Office

Merck Sharp & Dohme LLC

License Organization

Merck & Co., Inc.

Torii Pharmaceutical Co., Ltd.

ALK-Abello A/S

Drug Highest PhaseApproved

First Approval Date

Switzerland (24 Aug 2016),

Rhinitis, Allergic

Regulation-

Login to view timeline

The incidence of allergic rhinitis (AR) in Chinese adults was reported to be as high as 24.1% and 16.8% in children. The current symptomatic treatment has the disadvantage of poor efficacy and cannot change the natural course of the disease. Allergen immunotherapy (AIT) is the only causative treatment approved by the WHO, bringing a new option to patients with allergic diseases. The quality of allergen preparations is critical to the diagnosis and treatment of the disease, emphasizing the need for standardized preparations, and AIT treatment in the early stages of the disease may change the long-term progression of the disease. Recent studies have reported that the microbiome of patients with different efficacy of desensitization therapy is different and may be correlated with the clinical symptoms of patients, but no prospective studies have been reported.

Start Date20 Dec 2024

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

NCT06151938

/ Enrolling by invitationNot Applicable

A Prospective Observational Study Evaluating Relevance of Measurement Instruments in Assessing Effectiveness of ACARIZAX® in the Treatment of Moderate to Severe House Dust Mite Allergic Rhinitis With/Without Allergic Asthma in Chinese

The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR) with or without allergic asthma (AA) who are newly prescribed ACARIZAX® will be recruited for evaluation of the relevance of measurement instruments. The instruments referred to three patient-report scales of allergic rhinitis symptom and quality-of-life including the Daily symptom score (DSS), Standardised rhinoconjunctivitis quality-of-life questionnaire [RQLQ(S)], and Visual analogue scale (VAS). Other data will be collected to evaluate the effectiveness and safety of ACARIZAX® under real-world clinical practices.

Start Date21 Nov 2023

Sponsor / Collaborator

ALK-Abello A/S

100 Clinical Results associated with House dust mites allergenics extract(ALK-Abello A/S)

Login to view more data

100 Translational Medicine associated with House dust mites allergenics extract(ALK-Abello A/S)

Login to view more data

100 Patents (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

Login to view more data

32

Literatures (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

01 Jan 2025·PEDIATRIC PULMONOLOGY

Effect and mechanism of allergen‐specific immunotherapy on small airway dysfunction in children with asthma

Article

Author: Lin, Jie ; Dong, Wenfang ; Yin, Yong ; Wu, Jinhong ; Hong, Li ; Zhong, Wenwei ; Zhang, Lei ; Ying, Xiaolan ; Yang, Lin

Abstract:

Background:

The purpose of this study was to investigate the effectiveness of allergen‐specific immunotherapy (AIT) on small airway dysfunction (SAD) and the underlying mechanism with a special focus on basophils.

Methods:

Sixty‐five children with mild to moderate asthma who were under regular inhaled corticosteroid (ICS) treatment for more than 1 year but whose FEF75 remained below 65% of the predicted value and had positive results for serum Der p or Der f were enrolled. Children with asthma underwent house dust mite (HDM) subcutaneous immunotherapy (SCIT) treatment for 1 year. Clinical symptoms and lung function were evaluated every 3 months during HDM SCIT treatment. Basophil activation test (BAT) was carried out before and after HDM SCIT treatment. RNA sequencing was performed in isolated basophils from peripheral blood after 6 months of HDM SCIT treatment, followed by GO term and KEGG pathway enrichment analysis between patients with and without HDM SCIT treatment.

Results:

HDM AIT treatment ameliorated clinical symptoms while concurrently improved lung function parameters, such as FEV1/FVC, FEF75, FEF50 and MMEF (p < .05). It is worth noting that FEF75 values showed a highly significant, gradual and persistent increase (from 49.55 ± 1.27% at baseline to 71.89 ± 2.64% after 1 year of therapy) and 22 of 35 patients no longer had SAD after 1 year of treatment. BAT results revealed that AIT treatment significantly reduced basophil activity to the inhalant allergen mixtures containing HDM in vitro challenge from baseline. GO term and KEGG pathway enrichment analysis of basophils revealed that downregulated genes were mainly involved in immune cell activation, antigen presentation, and Th2 cell differentiation.

Conclusions:

Our study demonstrated that HDM AIT not only improved SAD related lung function parameters, but also reduced basophil activity. RNA sequencing revealed the inhibition of phagocytosis and the phagosome pathway in basophils which may affect the polarization of Th2 cell differentiation after HDM AIT.

01 Jan 2025·Lancet Regional Health-Europe

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial

Article

Author: Gagnon, Remi ; Emeryk, Andrzej ; Caimmi, Davide ; Schuster, Antje ; Pfaar, Oliver ; Nolte, Hendrik ; Foss-Skiftesvik, Majken Hougaard ; Østerdal, Anne Sofie ; Mikler, Jan ; Novakova, Silviya

Background:

Allergic rhinitis/rhinoconjunctivitis (AR/C) induced by house dust mites (HDM) often begins in childhood and negatively impacts a child's quality of life. The daily burden can be further compounded by comorbid asthma. Allergen immunotherapy is the only available treatment targeting the underlying cause of allergic disease. Efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT)-tablet has been demonstrated in adults and adolescents with HDM AR/C with or without asthma, but data are lacking for younger children.

Methods:

Phase III, randomised, double-blind, placebo-controlled trial in younger children (5-11 years) with HDM AR/C with or without asthma. Eligible subjects were randomised 1:1 to SQ HDM SLIT-tablet or placebo for ∼1 year and had free access to AR/C symptom-relieving medications. The primary outcome was the total combined rhinitis score (TCRS) during the final 8 weeks of the treatment period (∼1 year). Secondary outcomes included the rhinitis daily symptom score (DSS) and medication score (DMS), the rhinoconjunctivitis total combined score (TCS), and the Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score. Efficacy analyses were conducted on the full analysis set (observed cases). Asthma-related outcomes were also explored. The trial was registered on ClinicalTrials.gov: NCT04145219 and EudraCT: 2019-000560-22.

Findings:

A total of 1460 subjects were randomised to SQ HDM SLIT-tablet (n = 729) or placebo (n = 731). The primary outcome, TCRS, was statistically significantly different for SQ HDM SLIT-tablet (n = 693) versus placebo (n = 706), with an absolute difference of 1.0 (95% CI: 0.5, 1.4; p < 0.0001) corresponding to a relative reduction of 22.0% (95% CI: 12.0, 31.1). Key secondary outcomes (DSS, DMS, TCS, PRQLQ) showed statistically significant reductions in symptoms and medication use, and improved disease-related quality of life for SQ HDM SLIT-tablet versus placebo. Improvements in asthma symptoms and reduced asthma medication use indicated an additional effect of SQ HDM-SLIT tablet versus placebo. The SQ HDM SLIT-tablet showed a higher event rate for treatment-related adverse events (AEs) than placebo. Most events were of mild or moderate severity and few subjects discontinued due to AEs (2.5%).

Interpretation:

The trial confirmed the efficacy and safety of the SQ HDM SLIT-tablet for treating HDM AR/C in younger children (5-11 years) with or without asthma. The safety profile supports daily self-administration of the SQ HDM SLIT-tablet in children.

Funding:

ALK-Abellό, Hørsholm, Denmark.

12 Aug 2024·ACTA OTO-LARYNGOLOGICA

The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan

Article

Author: Masuno, Satoru

BACKGROUND:

Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases.

AIMS/OBJECTIVES:

To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions.

MATERIAL AND METHODS:

In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated.

RESULTS:

The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE^® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE^® patients with seven or more positive antigen types.

CONCLUSIONS AND SIGNIFICANCE:

Severe adverse reactions reduced early adherence.

17

News (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

06 May 2025

·ir.alk.net

Three-month interim report (Q1) 2025 (unaudited)

ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated. Total revenue increased by 12% to DKK 1,522 million (1,351). Europe and International markets delivered growth rates of 10% and 24% respectively. Revenue in North America bounced back with growth of 14%. Global tablet sales grew by 22% to DKK 857 million (706) on double-digit growth in all sales regions. European tablet sales grew by 17%, largely due to increase in new patients, while the positive growth impact of pricing decreased as anticipated compared to last year. Global SCIT and SLIT drops sales were unchanged at DKK 500 million (500), while sales of Other products and services was up 11% to DKK 165 million (145). Operating profit (EBIT) increased by 50% to DKK 469 million (316), driven by sales growth, improved gross margin, and cost savings after last year’s optimisation initiatives. The capacity cost-to-revenue ratio was down to 36% (42%). The EBIT margin of 31% (23%) partly reflected that Q1 typically is ALK’s most profitable quarter. Free cash flow almost tripled to DKK 330 million (111) mainly driven by increased earnings. CAPEX was unchanged at DKK 57 million (59). Financial highlights Allergy+ strategy highlights The launch of the house dust mite tablet for children positively impacted sales growth in Q1, and initial market response exceeded expectations. The tablet is currently available for young children in 12 countries. The tree tablet ITULAZAX® has recently been approved in Europe for treatment of young children and adolescents aged five to 17. Efforts to secure market access for the neffy®adrenaline nasal spray is progressing well, and ALK expects the first launches in Europe to start in Q3 2025. Initial market feedback has been encouraging. ALK has entered into a four-year agreement with US-based ARS Pharma to co-promote the neffy® adrenaline (epinephrine) nasal spray in the USA. The clinical phase 2 of the peanut allergy tablet is on track and patient recruitment continues. 2025 full-year outlook The full-year outlook remains unchanged, demonstrating a continuous, robust improvement in profitability: Revenue is still expected to grow by 9-13% driven by growth across all sales regions and product groups. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products. The EBIT margin is still expected to improve by 5 percentage points to around 25%, driven by revenue growth, improving gross margin, and optimisation efforts. Commenting on the Q1 results, CEO Peter Halling said: “ALK is off to a very good start in 2025, with sustained revenue growth, a significant increase in operating profit, and steady progress on our strategic agenda. The initial market response to the launch of our house dust mite tablet, ACARIZAX®, for use in young children has been encouraging, and we are excitedly preparing to launch neffy®, the new adrenaline nasal spray. Despite the turmoil in the markets from trade wars and tariffs, we remain optimistic about the year ahead, anticipating only a modest impact from tariffs considering our current business footprint." Hørsholm, 6 May 2025 ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Media: Maiken Riise Andersen, tel. +45 5054 1434 ALK is hosting a conference call for analysts and investors at 11.00 a.m. (CEST) on 6 May 2025 at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation will be available shortly before the call begins. To register for the conference call, please use this link and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register well in advance and to call in before 10.55 a.m. (CEST). Attachment Company release_10_25UK_060525_Q1 25 interim report

Financial StatementDrug ApprovalPhase 2

05 Mar 2025

·www.drugs.com

FDA Expands Indication of Dust Mite Allergy Drug to Include Young Children

WEDNESDAY, March 5, 2025 -- The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to include children ages 5 through 11 years. Odactra is an allergy immunotherapy and is administered sublingually as a small tablet that dissolves under the tongue. The approval was based on data from a phase 3 clinical trial that included 1,460 children ages 5 to 11 years old with persistent allergic rhinitis symptoms for a year, despite receiving symptom-relieving medication. Children randomly assigned to Odactra experienced a relative reduction in total combined rhinitis score of 22 percent versus placebo. Four patients receiving Odactra experienced severe treatment-related adverse events, including oral and ear itchiness, burning or tingling sensation in the mouth, lip swelling, and abdominal pain. However, no participants reported treatment-related anaphylaxis or adverse events requiring treatment with epinephrine. "The pediatric indication for Odactra is significant because it provides physicians and parents a new option for treating these younger patients," Jackie Eghrari-Sabet, M.D., an allergist and immunologist at George Washington University in Washington, D.C., said in a statement . "In addition to the convenience of sublingual administration, Odactra has been shown to reduce their allergy symptoms and reliance on symptomatic medications." Expanded approval of Odactra was granted to ALK. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultPhase 3ImmunotherapyDrug Approval

27 Feb 2025

·ir.alk.net

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication. The FDA approval is an important step in ALK’s efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults - in all relevant markets. ALK’s Executive Vice President of R&D, Henriette Mersebach (MD), says: “I’m very pleased with the FDA approval of ODACTRA® in young children, as this will enable us to provide an important and potentially life-changing treatment option for children who experience troublesome symptoms and impaired quality of life related to their allergic disease. Building upon our longstanding commitment to developing evidence-based innovative medicines, we now look forward to making ODACTRA® available for children through our US prescriber networks and through commercial and government markets.” The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, which involved 1,460 children in North America and Europe. The trial demonstrated efficacy and safety of the treatment in children, and the results were recently published in the reputable scientific journal, The Lancet Regional Health – Europe. Globally, it is estimated that more than ten million children, aged five to 11, have uncontrolled respiratory allergies and the number is growing. House dust mites are a common cause of allergy and closely linked to asthma. ALK’s house dust mite allergy tablet is marketed as ODACTRA® in USA, as ACARIZAX® in Europe and several international markets, as MITICURE™ in Japan, and as Sensimune™ in India. Until now, the tablet has been approved for use in young children in Europe and in Japan. A corresponding regulatory review is currently ongoing in Canada. Furthermore, a separate regulatory review of ALK’s tree tablet ITULAZAX® also for use in children is currently ongoing in Europe and Canada. These reviews are expected to complete in 2025, after which all ALK’s tablets will be approved for children, adolescents, and adults in relevant markets. The approval is not expected to affect ALK’s financial outlook for 2025. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment Company release_04_25UK_270225_ODACTRA_approval_children

ImmunotherapyDrug ApprovalPhase 3Clinical Result

100 Deals associated with House dust mites allergenics extract(ALK-Abello A/S)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V01AA03	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Asthma	South Korea	Abbott Laboratories	02 Jan 2018
Conjunctivitis	Canada	Merck Canada, Inc.	04 May 2017
Epilepsy, Idiopathic Generalized	Canada	Merck Canada, Inc.	04 May 2017
House dust mite allergy	Canada	Merck Canada, Inc.	04 May 2017
allergic rhinitis due to dust mite	United States	ALK-Abello A/S	01 Mar 2017
Rhinitis, Allergic	Switzerland	ALK-Abello A/S	24 Aug 2016

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allergic rhinoconjunctivitis	Phase 3	China	ALK-Abello A/S	06 Nov 2019
Allergic rhinoconjunctivitis	Phase 3	China	Danish Alkai--Abeyo Company Beijing Representative Office	06 Nov 2019
Allergic asthma	Phase 3	Belarus	Abbott Laboratories	01 Oct 2015
Allergic asthma	Phase 3	Russia	Abbott Laboratories	01 Oct 2015
Anaphylaxis	Phase 3	Belarus	Abbott Laboratories	01 Oct 2015
Anaphylaxis	Phase 3	Russia	Abbott Laboratories	01 Oct 2015
Rhinitis, Allergic, Perennial	Phase 3	-	ALK-Abello A/S	01 Jan 2013
Rhinitis, Allergic, Perennial	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jan 2013
Rhinoconjunctivitis	Phase 3	-	ALK-Abello A/S	01 Jan 2013
Rhinoconjunctivitis	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jan 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04145219 (MT-12, Literature) Manual	Phase 3	allergic rhinitis with asthma	1,460	SQ HDM SLIT	dtihpvicro(enofqgscdz): Difference = 1.0 (95% CI, 0.5 - 1.4), P-Value = < 0.0001 View more	Positive	26 Nov 2024
				Placebo
NCT04145219 (MATIC \| phase 3 \| MT-12, CTgov)	Phase 3	Rhinoconjunctivitis \| allergic rhinitis due to dust mite \| Asthma	1,460	HDM (HDM SLIT-tablet (12 SQ-HDM))	izymxawfid(gndledebvx) = ssgbjuefkq ahztrzxeeu (aksyaffcpe, 0.3) View more	-	12 Jun 2024
				Placebo (Placebo SLIT-tablet)	izymxawfid(gndledebvx) = luwxmpoykl ahztrzxeeu (aksyaffcpe, 0.3) View more
NCT03654976 (MAPIT, CTgov)	Phase 3	Rhinitis, Allergic \| Allergic asthma \| House dust mite allergy	533	HDM (HDM SLIT-tablet (12 SQ-HDM))	wzwuytdwny(mkzzluvppt) = wmxueofela rmztndiwgh (gtfxtgiqbq, ghjiyojihu - dxhcparwok) View more	-	19 Oct 2023
				Placebo (Placebo SLIT-tablet)	wzwuytdwny(mkzzluvppt) = xguoicvnky rmztndiwgh (gtfxtgiqbq, wxjrugtfjh - cffoczhkcn) View more
NCT04541004 (AMASE, CTgov)	Phase 3	Rhinoconjunctivitis \| Asthma \| Rhinitis, Allergic	253	HDM SLIT-tablet	ltecgsjjwy = hljkejnpuf acthkxbjem (seqvhjlgsr, hofgaquujn - szgcbcwetl) View more	-	03 Jul 2023
NCT02596321 (CTgov)	Phase 3	Rhinitis, Allergic \| Allergic asthma \| Anaphylaxis	112	Mitizax (Mitizax ALK HDM Tablet)	pgecqtsrvd(gvgmnmoori) = alhqqmvkdt hiamraudif (ldbikiuemd, 1.183) View more	-	18 Dec 2017
				Placebo (Placebo Tablet)	pgecqtsrvd(gvgmnmoori) = wkxsfzpwju hiamraudif (ldbikiuemd, 0.067) View more
NCT01700192 (P05607 \| trial A, CTgov)	Phase 3	allergic rhinitis due to dust mite \| Rhinoconjunctivitis \| Asthma ... View more	1,482	Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+MK-8237 tablets+Rescue Medication: Mometasone furoate nasal spray+Loratadine (MK-8237)	ygxruxpumz(bhwoitsbtu) = eujtvxedwf mjzluxntif (tfdrggjjah, 3.55) View more	-	03 Mar 2017
				Placebo tablets+Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+Rescue Medication: Mometasone furoate nasal spray+Loratadine (Placebo)	ygxruxpumz(bhwoitsbtu) = yzowrxemli mjzluxntif (tfdrggjjah, 3.82) View more
NCT01678807 (8237-008 \| MK-8237-008, CTgov)	Phase 1	Rhinitis, Allergic, Perennial \| House dust mite allergy	195	MK-8237 12 DU (MK-8237 12 DU)	sbceyxkglw = nkydcczlgp jqzlxexruz (jgsklzxzub, moderpfmag - tyjkrjlftq) View more	-	13 Feb 2017
				MK-8237 6 DU (MK-8237 6 DU)	sbceyxkglw = egosdmurap jqzlxexruz (jgsklzxzub, teqladtocz - kebefzhxej) View more
NCT01644617 (P07627 \| 8237-003, CTgov)	Phase 2	Rhinoconjunctivitis \| Rhinitis, Allergic, Perennial \| House dust mite allergy	124	MK-8237 12 DU (MK-8237 12 DU)	stdflgezum(oxjbrnszwv) = tfmxpykiof jziavzgdle (jknaavbbzc, ozkkidfouh - vpcdcgmeat) View more	-	13 Feb 2017
				Placebo (Placebo)	stdflgezum(oxjbrnszwv) = luzuemsqif jziavzgdle (jknaavbbzc, chwrrooyna - dfreqisuqz) View more
NCT01852825 (8237-009, CTgov)	Phase 1	Rhinoconjunctivitis \| allergic rhinitis due to dust mite	26	NAC+MK-8237 (NAC + MK-8237 (Part 2))	gdtdcioqow(xuwferviwf) = arleizftkf ficdahoiaa (fcbntdqbvf, efqcxqvjqt - fcddzwyocz) View more	-	13 Feb 2017
				Placebo (NAC + Placebo (Part 2))	gdtdcioqow(xuwferviwf) = xppclxynar ficdahoiaa (fcbntdqbvf, qklrwwbuol - drjgohecjk) View more
NCT01700192 (Pubmed \| J Allergy Clin Immunol) Manual	Phase 3	Asthma \| Allergic rhinoconjunctivitis	1,482	MK-8237	bkinneoeoh(qsfywphdcg) = vfjngapddg nahiznmzes (qtoctyxxts, 10 - 25) View more	Positive	01 Dec 2016
				Placebo	-

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data